Study Summary
The researchers are doing this study to see if early reinfusion of tisagenlecleucel can keep participants in B-CEll ApLasia at 6 months after their first infusion. The researchers will also look at the safety of early reinfusion and how effective it is at treating B-ALL.
Want to learn more about this trial?
Request More InfoInterventions
TisagenlecleucelBIOLOGICAL
Tisagenlecleucel will be infused based on institutional guidelines. Reinfusion of tisagenlecleucel will occur 30-60 days following the first dose.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Children's Hospital of Los Angeles (Data Collection Only) | Los Angeles | California | United States |
| Stanford University (Data Collection Only) | Stanford | California | United States |
| Children's Hospital Colorado (Data Collection Only) | Aurora | Colorado | United States |
| Johns Hopkins University (Data Collection Only) | Baltimore | Maryland | United States |
| Memorial Sloan Kettering Cancer Center | New York | New York | United States |
| Cincinnati Children's Hospital Medical Center (Data Collection Only) | Cincinnati | Ohio | United States |